Scarica l'app Stockscreener
55.50
3.04%
-1.74
Dopo l'orario di chiusura:
55.50
Precedente Chiudi:
$57.24
Aprire:
$56.42
Volume 24 ore:
2.32M
Relative Volume:
1.08
Capitalizzazione di mercato:
$10.67B
Reddito:
$3.24B
Utile/perdita netta:
$348.90M
Rapporto P/E:
31.15
EPS:
1.7817
Flusso di cassa netto:
$717.02M
1 W Prestazione:
-0.09%
1M Prestazione:
-7.10%
6M Prestazione:
-0.13%
1 anno Prestazione:
-18.76%
Intervallo 1D:
$54.54
$56.55
Intervallo di 1 settimana:
$53.94
$57.50
Portata 52W:
$50.76
$68.54
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
55.50 | 10.67B | 3.24B | 348.90M | 717.02M | 1.7817 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-20 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Downgrade | Stifel | Buy → Hold |
| 2025-09-08 | Iniziato | H.C. Wainwright | Neutral |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Perpetual Ltd Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance Australia
Here Is Why BioMarin (BMRN) Is Projected to Rally - MSN
BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BMRN Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
BioMarin Pharmaceutical (BMRN) receives FDA approval for expanded use of PALYNZIQ in adolescents - MSN
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BioMarin at TD Cowen Conference: Strategic Growth Amid Challenges - Investing.com
BioMarin Pharmaceutical Inc. (BMRN) rated overweight at Wells Fargo despite Voxzogo phase 2 study discontinuations - MSN
Here is Why BioMarin (BMRN) is Projected to Rally - Insider Monkey
What BioMarin Pharmaceutical (BMRN)'s Voxzogo Trial Stops and Mixed Safety Data Mean For Shareholders - Sahm
BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations - Insider Monkey
5 Quality Value Stocks Likely to Make a Comeback According to Analysts - Insider Monkey
BMRN SEC FilingsBiomarin Pharmaceutical Inc 10-K, 10-Q, 8-K Forms - Stock Titan
(BMRN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Exploring High Growth Tech Stocks In The US Market March 2026 - simplywall.st
Vanguard disaggregates holdings; BioMarin (NASDAQ: BMRN) shows 0 shares reported - Stock Titan
BioMarin Bests Ascendis in Appeal Over Patent Suit Stay (1) - Bloomberg Law News
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Increased to Strong-Buy at Truist Financial - marketbeat.com
BioMarin (BMRN) down 13.6% since last earnings report: Can it rebound? - MSN
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Assenagon Asset Management S.A. Raises Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Swiss Life Asset Management Ltd Sells 54,282 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN
RNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool
BioMarin Pharmaceutical (BMRN) reports positive results from ongoing trials of VOXZOGO - msn.com
Top 3 Health Care Stocks That Are Set To Fly In March - Benzinga
BioMarin (BMRN) legal chief has 1,273 shares withheld for taxes - Stock Titan
BioMarin (BMRN) CTO reports 1,693-share tax withholding, holds 84,140 - Stock Titan
BioMarin (NASDAQ: BMRN) CFO has 2,117 shares withheld for tax - Stock Titan
BioMarin (BMRN) CEO reports tax-withholding share disposition - Stock Titan
Hudson Bay Capital Management LP Increases Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin (BMRN) EVP Hubbard receives stock awards and withholds shares for tax - Stock Titan
BioMarin (NASDAQ: BMRN) EVP granted stock, options and covers tax with shares - Stock Titan
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease - TipRanks
BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? - MSN
[Form 4] BIOMARIN PHARMACEUTICAL INC In... - Stock Titan
BioMarin (NASDAQ: BMRN) CFO gets stock grants and tax share withholding - Stock Titan
BioMarin (BMRN) CEO granted 89,200 options and 62,440 RSUs in 2026 awards - Stock Titan
Price-Driven Insight from (BMRN) for Rule-Based Strategy - Stock Traders Daily
Wolfe Research Maintains Outperform on BioMarin (BMRN) March 16, 2026 - Meyka
BioMarin Pharmaceutical Inc. 8-K Filing: Company Information, Address, and Stock Details (March 16, 2026) - Minichart
Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN) - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap DownTime to Sell? - MarketBeat
BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma
Wolfe Research reiterates Outperform on BioMarin stock at $95 By Investing.com - Investing.com India
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):